Tuesday, 10 March 2026
PERSPECTA
News from every angle
All
World
Politics
Business
Technology
Finance
Science
Health
Sport
Culture
Opinion
Environment
← Back to headlines
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
9 Mar, 08:46 — 9 Mar, 08:46
Post
Share
Copy link
Embed
Sources
Sort: Relevance
Sort: Latest
Sort: Bias (L→R)
Sort: Bias (R→L)
Sort: Factuality
left
center
right
Showing 1 of 1 sources
Yahoo
Mostly Factual
17h ago
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
Read full article →
Something wrong with this story? Report an issue
Related Stories
High HPV awareness, but barriers stall PH vaccination
just now
Baguio Health Office expands services to include eye test
just now
African hospitals under digital attack, Microsoft executive warns
just now
Doctors’ suspension: Medical directors demand fairness, balance in disciplinary actions
just now
Tuesday, 10 March 2026
Explore
Log in
Sign up
PERSPECTA
News from every angle
